Tandem Diabetes Care (NASDAQ:TNDM) Stock Gets Price Target Boost from Barclays

Tandem Diabetes Care (NASDAQ:TNDM) had its price objective increased by equities researchers at Barclays from $18.00 to $20.00 in a report issued on Friday, Benzinga reports. The brokerage presently has an “equal weight” rating on the medical device company’s stock. Barclays‘s price target suggests a potential upside of 20.31% from the stock’s previous close.

A number of other brokerages also recently commented on TNDM. UBS Group assumed coverage on Tandem Diabetes Care in a research note on Tuesday, July 28th. They issued a “neutral” rating and a $18.00 target price for the company. Wells Fargo & Company dropped their price target on Tandem Diabetes Care from $27.00 to $25.00 and set an “overweight” rating on the stock in a research report on Friday. Citigroup cut their price target on Tandem Diabetes Care from $24.00 to $20.00 and set a “neutral” rating on the stock in a report on Wednesday, September 30th. William Blair initiated coverage on Tandem Diabetes Care in a report on Friday, August 21st. They issued an “outperform” rating on the stock. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $26.00 price objective (down from $30.00) on shares of Tandem Diabetes Care in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Tandem Diabetes Care has an average rating of “Hold” and an average target price of $27.18.

Tandem Diabetes Care Stock Performance

Shares of Tandem Diabetes Care stock traded down $1.37 during trading hours on Friday, reaching $16.62. The company’s stock had a trading volume of 2,307,745 shares, compared to its average volume of 2,138,377. The company’s 50 day simple moving average is $17.74 and its 200 day simple moving average is $18.90. The company has a debt-to-equity ratio of 4.62, a quick ratio of 2.65 and a current ratio of 3.18. Tandem Diabetes Care has a one year low of $12.26 and a one year high of $29.65. The stock has a market cap of $1.16 billion, a P/E ratio of -17.88 and a beta of 1.59.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings results on Thursday, November 5th. The medical device company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.15. Tandem Diabetes Care had a negative net margin of 6.08% and a negative return on equity of 45.97%. The business had revenue of $283.69 million during the quarter, compared to analyst estimates of $265.85 million. During the same period in the previous year, the business posted ($0.31) EPS. The company’s quarterly revenue was up 13.8% on a year-over-year basis. As a group, analysts expect that Tandem Diabetes Care will post -0.66 EPS for the current fiscal year.

Insider Buying and Selling

In other Tandem Diabetes Care news, Director Christopher J. Twomey sold 1,700 shares of the company’s stock in a transaction dated Tuesday, October 27th. The shares were sold at an average price of $19.15, for a total value of $32,555.00. Following the completion of the transaction, the director owned 24,434 shares in the company, valued at approximately $467,911.10. This represents a 6.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On Tandem Diabetes Care

Hedge funds and other institutional investors have recently made changes to their positions in the business. Integrated Wealth Concepts LLC bought a new stake in shares of Tandem Diabetes Care during the 2nd quarter worth about $33,000. Sterling Capital Management LLC boosted its holdings in shares of Tandem Diabetes Care by 849.0% in the third quarter. Sterling Capital Management LLC now owns 2,325 shares of the medical device company’s stock valued at $38,000 after acquiring an additional 2,080 shares in the last quarter. Fulcrum Asset Management LLP boosted its holdings in shares of Tandem Diabetes Care by 1,463.6% in the third quarter. Fulcrum Asset Management LLP now owns 4,378 shares of the medical device company’s stock valued at $73,000 after acquiring an additional 4,098 shares in the last quarter. Provenance Wealth Advisors LLC acquired a new position in shares of Tandem Diabetes Care during the third quarter valued at approximately $158,000. Finally, Prosperitas Financial LLC acquired a new position in shares of Tandem Diabetes Care during the second quarter valued at approximately $151,000.

Tandem Diabetes Care News Summary

Here are the key news stories impacting Tandem Diabetes Care this week:

• Positive Sentiment: Third-quarter revenue was $283.7 million, up 13.8% year over year and above analyst expectations. The loss of $0.10 per share was also narrower than estimates, while gross margin rose to 57%—up 270 basis points year over year. Tandem third-quarter 2026 results
• Positive Sentiment: Management projected 2026 sales of $1.065 billion to $1.085 billion, supporting the growth outlook. 2026 sales outlook and CEO transition
• Neutral Sentiment: Jeannette Bankes was named president and CEO, with the transition set for the end of 2026 as John Sheridan retires. A named successor provides clarity, though investors may watch for execution through the handoff. CEO appointment
• Negative Sentiment: Wells Fargo lowered its price target from $27 to $25, a sign of a more cautious valuation view, although it kept an Overweight rating and the revised target remains above the quoted share price. Wells Fargo price target update

About Tandem Diabetes Care

Tandem Diabetes Care, Inc is a medical device company focused on developing and commercializing advanced insulin delivery systems for people with diabetes. The company’s products are designed to help automate and simplify insulin therapy while supporting integration with continuous glucose monitoring (CGM) technology.

Tandem’s product portfolio includes the t:slim X2 Insulin Pump and the compact Tandem Mobi system, along with insulin cartridges, infusion sets, accessories and diabetes management software.